(DRIO) DarioHealth - Ratings and Ratios

DarioHealth Corp (NASDAQ:DRIO) is a digital health company operating in the United States, Canada, the European Union, Australia, and New Zealand. The company specializes in delivering personalized digital therapeutics and dynamic interventions through its platform, leveraging data analytics and one-on-one coaching. Its solutions address chronic conditions such as diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The product portfolio includes Dario Evolve, a metabolic health solution for diabetes, pre-diabetes, hypertension, and weight management; Dario Move, targeting common musculoskeletal conditions; Dario Elevate, a behavioral health solution optimizing evidence-based care access; and Dario One, a comprehensive suite for chronic condition management. Additionally, the company offers native devices, including glucose meters, blood pressure cuffs, digital scales, and biofeedback sensors, alongside live coaching services. DarioHealth Corp, formerly known as LabStyle Innovations Corp, was incorporated in 2011 and is headquartered in New York, New York.

Based on and , the 3-month forecast for DRIO indicates potential volatility. The stock is currently trading at $0.73, with a 20-day SMA of $0.68 and a 50-day SMA of $0.72, suggesting near-term stability. However, the 200-day SMA of $0.95 indicates downside pressure. The ATR of 0.12 signals moderate volatility. Fundamentally, the market cap of $26.71M and P/S ratio of 1.16 reflect its small-cap status and revenue multiple. The negative RoE of -59.16% highlights profitability challenges. Overall, the stock may face headwinds but could stabilize near current levels if revenue growth accelerates.